ProBioGen expands protein and viral vector manufacturing
German CDMO ProBioGen has announced significant expansion of its biomanufacturing capabilities through commissioning of an additional 1000L GMP production line for protein therapeutics and completion of a new viral vector manufacturing unit at its Berlin facilities.
The development of next-generation biologic therapies, including viral vectors for gene therapy applications, requires increasingly sophisticated manufacturing capabilities. ProBioGen’s latest expansion aims to address these evolving needs while maintaining regulatory compliance and process optimisation.
The additional 1000L GMP production line strengthens ProBioGen’s protein manufacturing capacity, specifically targeting the growing global biologics sector. The company’s integrated approach combines its proprietary CHO.RiGHT platform with established technologies, including the DirectedLuck transposase system and GlymaxX ADCC enhancement technology, to optimise production processes across its dual manufacturing sites.
Viral vector capabilities enhanced through specialised platforms
In the viral vector division, the company has developed customised manufacturing platforms that extend beyond conventional processes. These platforms specifically address the production requirements for lentiviral and adeno-associated viral vectors, alongside virus-like particles. The expanded facilities support stable cell line development tailored to these specialised applications, incorporating risk mitigation strategies and comprehensive analytical support.
Technical specifications
The new viral manufacturing unit provides GMP-compliant production capabilities up to 200L scale. This is supported by the company’s proprietary cell lines, including the RIGHT and
AGE1.CR.pIX platforms, which have been optimised for viral vector production. The facility incorporates early-stage risk detection systems and maintains comprehensive analytical and regulatory documentation processes.
According to Dr Alfred Merz, Chief Executive Officer at ProBioGen: “These strategic initiatives mark a major milestone for us as we continue to grow and better fulfil our customer’s needs.”
Founded in 1994 as a Charité hospital spin-off, ProBioGen has evolved into a globally operating CDMO with approximately 300 employees across three Berlin locations. The company’s expansion strategy focuses on extending its service value chain through organic growth and strategic acquisitions, while maintaining emphasis on biopharmaceutical development capabilities.
The combination of expanded manufacturing capacity and specialised technological platforms positions ProBioGen to support the increasing complexity of biological therapeutics development, from initial cell line development through to commercial-scale manufacturing.
For further technical specifications and information, visit:www.probiogen.de
Digital issue: Please click here for more information
